The Latest Breaking News from Novartis

The European Commission has no plans to withdraw or revise its proposed overhaul of EU pharmaceutical rules, despite mounting pressure from the pharmaceutical industry concerned about potential tariffs and the sector’s competitiveness.

Trump's administration is blowing hot and cold on pharmaceutical products, which initially benefited from exemptions in the round of tariffs announced on April 2.

Eugene Levy’s trademark eyebrows fly off for Little Caesars

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Novartis reports positive Phase 3B results for Fabhalta in PNH patients, highlighting improved hemoglobin levels and consistent safety profile after 24 weeks.

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE:NVS), for its

Stop being afraid of newfangled technology, and start letting your kids use it to help them with their homework, said panelists at Fortune Global Forum.

A year after spinning off its generics business to become a "pure-player" developer of innovative medicines, Novartis registered a 15 percent increase in its core net profit to $4.1 billion during the July-September period, from the same quarter last year.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…